TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pharmacodynamic interaction assessed by ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30-days rehospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to Any Referral for Oncologic/Renal Cell Carcinoma (RCC) Related Care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time From Nephrectomy to Receipt of First-line Adjuvant Systemic Therapy (AST)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness of strict glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ArmeoSenso - hand workspace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vitamin D (25-hydroxyvitamin D) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of acid exposure in the distal esophagus and proximal stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline Interleukin-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative morphine requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Apoptosis imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in minimal hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occlusal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Pathological Response Rate (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-immune geometric mean titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall seroconversion rates (SCRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: In stent neointimal hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants Classified According to IGF-I Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Metabolic syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change from baseline of the total severity score of the CAPS-5 interview
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Moderate to Severe Contact Dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Uncorrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ASASHI-NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at Time of Osmotic Dilator Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of the patients
Endpoint domain: Mortality/survival
Primary endpoint: Mean percentage change of Levothyroxine dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maternal attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Edinburgh depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postpartum anxiety scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stable Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progressive Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative contributions of large artery disease and microvascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of the IMP
Endpoint domain: Adverse events/effects
Primary endpoint: Humoral immuneresponse to the IMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetics of viral genomes [Vg]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WOMAC Pain Subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Time Up & Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c (glycosylated haemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-reported abstinence biochemically verified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum suPAR level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Α-amylase activity in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secretory immunoglobulin class A concentration in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cortisol concentration in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Testosterone concentration in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 6 Month Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in bone innervation (presence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of pain in patients with firstly-diagnosed myeloma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in quality of life in myeloma after first-line treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clavien-Dindo grade
Endpoint domain: Adverse events/effects
Primary endpoint: Change in VO2 (oxygen consumption, ml/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum Concentration (Cmax) of Ixekizumab (Single Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration From Time Zero to Infinity (AUC 0toinf) of Ixekizumab (Single Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Ixekizumab (Multiple Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration From Time Zero to 336h (AUC 0 to 336h) of Ixekizumab (Multiple Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood alcohol concentration > 1.0 per mille
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol consumption > 40 g/day (females) or > 60 g/day (males)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continuous intake of alcohol during more than 5 consecutive days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure less than 140/90 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tumor Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in prostate volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Quality of Life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of HIV-infected adults who have CD4 count ≤ 100 cells/μL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Twelve (12) month all-causes and cryptococcal meningitis (CM)-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: change from baseline in percent atheroma volume (PAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Laboratory coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall survival after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Change in serum potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin Health (overall)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Laboratory Confirmed EV71-Associated Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Patient's Assessment of Arthritis Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family members' depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient centeredness of care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Time Spent in Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Clearance Rate of AK Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Energy intake in kilojoules and kilocalories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cortical fractional interstitial fibrosis volume (V IntFib)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymph node count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Vaginal delivery
Endpoint domain: Mortality/survival
Primary endpoint: Social and emotional development of infants
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite Responders Consistency Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The amount of AZD5718 excreted (Ae)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of AZD5718 excreted and expressed as a percentage of the administered dose (Fe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum plasma concentration (cmax) for AZD5718 and total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIHSS Score at 90 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participants acceptability of intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: elongation of capsular repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on learning tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score on test of attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score on measures of behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxygen uptake during cardiopulmonary exercise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Initiation of Long Acting Reversible Contraception
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anxiety, Depression and Irritability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Montgomery-Asberg Depression Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Auto-antibodies dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specific lymphocytes populations count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anger-out
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anger-in
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Consistent Connective Tissue Integration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: efficacy of motivational intervention in treating overweight and obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal placental invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Mean Sitting Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory associated pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sustained Headache Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operator rated cough VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operator rated overall procedure satisfaction VAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensory Threshold for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensation Ratings for Pain and Gas at 30 mm Hg Distension Above Baseline Operating Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial Colonic Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial Motility Index Over 30 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of early pregnancy loss
Endpoint domain: Mortality/survival
Primary endpoint: Coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood oxygen level dependent (BOLD) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: best-corrected visual acuity (BCVA) at month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central macular thickness (CMT) at month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the number of intravitreal injections of Ranibizumab at month 6
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number and Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of capsulorhexis and in-the-bag implantation of an intraocular lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Proven or Probable Invasive Fungal Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects Alive and Off of Oxygen at Day 14
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of Ischemic Stroke
Endpoint domain: Mortality/survival
Primary endpoint: mesh shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: declarative memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: executive skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score day 1 after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of vaccination with one or more needed vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Likelihood of vaccination with Tdap vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Likelihood of vaccination with MCV4 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Likelihood of vaccination with HPV vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of treatment-emergent AEs (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of treatment-emergent AEs (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of Bapotulimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of undertriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mistriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Observed Maximum Plasma Concentration (Cmax) of Saxagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Maximum Plasma Concentration (Cmax) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Half-life (t1/2) of Saxagliptin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areal bone mineral quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolism (uptake, distribution, and clearance) of [11C] JNJ-42491293 in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and tolerability as determined by number of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: analgesic scale (VAS assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypnotic drug discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Zinc Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New Fever
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Glycosylated Haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient-reported headache-free days per week
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hospital Mortality at 60 days
Endpoint domain: Mortality/survival
Primary endpoint: mean difference in cumulative costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Endocan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Complement levels (C3 and C4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of recurrence of eschar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Drug exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in externalizing behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in hyperactivity/inattention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in diagnostic status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Progression of Joint Space Narrowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in response from baseline to final follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in MADRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of manual rotation of the fetal occiput
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Serum Brain-derived Neurotrophic Factor (BDNF) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quantitative Electroencephalogram (QEEG) Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: long-term safety data
Endpoint domain: Adverse events/effects
Primary endpoint: Withdrawal from immunosuppressive drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in WOMAC Composite Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation for >1 week due to intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Proven/probable invasive pulmonary aspergillosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: WOMAC Pain Subscale
Endpoint domain: Life impact
Endpoint subdomain: Pain